Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMA vs CARISOPRODOL COMPOUND
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Centrally acting muscle relaxant; acts at brainstem reticular formation and spinal cord levels to inhibit polysynaptic reflexes, possibly via GABAergic and monoaminergic pathways.
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
Acute musculoskeletal pain (FDA-approved),Off-label: chronic low back pain, muscle spasms associated with neurological disorders
Relief of discomfort associated with acute, painful musculoskeletal conditions,As an adjunct to rest, physical therapy, and other measures
250 mg to 350 mg orally three times daily and at bedtime.
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
1-2 hours; prolonged to 3-4 hours in hepatic impairment; parent drug rapidly cleared via CYP2C19 metabolism to meprobamate (active, t1/2 6-16 hours).
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
Hepatic via CYP2C19 and CYP3A4; also undergoes dealkylation and hydroxylation.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite). Aspirin is hydrolyzed by esterases in the liver and plasma to salicylic acid, which is further conjugated. Codeine is metabolized by CYP2D6 to morphine (active) and by CYP3A4 to norcodeine.
Renal: ~60-70% as metabolites (including meprobamate and glucuronide conjugates); fecal: minimal; biliary: negligible.
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
~60% bound to albumin.
Carisoprodol is approximately 60% bound to plasma proteins, mainly albumin.
0.7-1.0 L/kg; consistent with moderate tissue distribution.
Volume of distribution is approximately 0.6–0.8 L/kg, indicating distribution into total body water.
Oral: ~100% (rapidly and completely absorbed).
Oral bioavailability is nearly complete (close to 100%) due to rapid and extensive absorption.
No specific dose adjustment guidelines; use with caution in severe renal impairment (GFR <30 m L/min).
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-moderate impairment; use caution.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in mild to moderate impairment; reduce dose or extend dosing interval.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment, reduce dose or increase interval; specific guidelines not established.
Not recommended for children under 12 years of age. For adolescents, adult dosing may be considered based on weight and clinical judgment.
Not recommended for pediatric patients due to aspirin content and risk of Reye syndrome.
Initiate at lower doses (e.g., 250 mg three times daily) due to increased sensitivity and risk of CNS adverse effects; monitor renal function.
Initiate at lowest effective dose; monitor for CNS depression, falls, and aspirin-related bleeding. Avoid in patients ≥65 years due to risks of dizziness, sedation, and GI bleeding.
None
None
May cause sedation, dizziness, and impaired psychomotor function; avoid driving or operating machinery.,Risk of abuse, dependence, and withdrawal; use with caution in patients with substance use disorder.,Concomitant use with alcohol or other CNS depressants may potentiate effects.,Elderly patients more sensitive to anticholinergic effects; monitor for confusion or falls.,Hepatic impairment: reduce dose or avoid use.,Pregnancy: limited data; use only if clearly needed.
Risk of dependence, abuse, and withdrawal with carisoprodol and codeine,CYP2D6 ultrarapid metabolizers may have morphine toxicity from codeine,Reye's syndrome risk in children with viral illness (aspirin),GI bleeding risk with aspirin,Respiratory depression with codeine,Sedation and impaired motor function,Hepatic impairment,Renal impairment
Hypersensitivity to carisoprodol or its components,Acute intermittent porphyria,Concurrent use with other CNS depressants (relative)
Hypersensitivity to carisoprodol, meprobamate, aspirin, codeine, or any component,Porphyria,Acute intermittent porphyria,Children with viral illness (aspirin) due to Reye's syndrome risk,Breastfeeding (codeine),Severe renal or hepatic impairment,GI bleeding or peptic ulcer disease (aspirin),Concurrent use of MAOIs or within 14 days,Respiratory depression (codeine)
No specific food interactions reported. Avoid alcohol and grapefruit juice as they may enhance sedative effects.
Avoid alcohol and grapefruit juice. Alcohol increases CNS depression and risk of hepatotoxicity. Grapefruit juice may inhibit metabolism, leading to increased levels and toxicity.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal resorptions and skeletal anomalies. Second/third trimester: Risk of neonatal withdrawal syndrome (irritability, hypertonia) with chronic maternal use near term.
Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fetal harm if used during the first trimester due to possible neural tube defects based on limited reports. In the second and third trimesters, maternal use may cause neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and respiratory depression if used near term. Carisoprodol is not recommended during pregnancy unless benefit outweighs risk.
M/P ratio unknown. Carisoprodol and its active metabolite meprobamate are excreted in breast milk. Potential for sedation in nursing infants. Use caution; monitor infant for drowsiness and feeding difficulties.
Carisoprodol is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2-4 based on small studies. An infant would receive a weight-adjusted dose of about 4-8% of the maternal dose, which may cause sedation, drowsiness, or irritability in the neonate. Breastfeeding is not recommended during carisoprodol use, especially in premature infants or those with hepatic impairment. If used, monitor infant for signs of CNS depression.
No pharmacokinetic studies in pregnancy. Use lowest effective dose for shortest duration; avoid chronic use due to risk of dependence and neonatal withdrawal.
No specific dosing adjustments for carisoprodol are established in pregnancy. However, due to increased plasma volume and altered hepatic metabolism in pregnancy, the drug's half-life may be reduced. Clinical monitoring for efficacy and maternal side effects (e.g., drowsiness, dizziness) is recommended. Use the lowest effective dose for the shortest duration. Consider avoidance of the compound formulation with aspirin or other NSAIDs, which have additional risks.
SOMA (carisoprodol) is a centrally acting skeletal muscle relaxant metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with porphyria. Use lowest effective dose for shortest duration (max 2-3 weeks). Monitor for sedation and dizziness, especially when combined with other CNS depressants. Taper to avoid withdrawal if used long-term.
Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential; use cautiously in patients with history of substance abuse. Combination with other CNS depressants (e.g., alcohol, benzodiazepines) increases sedation risk. Limit use to 2-3 weeks due to lack of efficacy beyond that and risk of dependence. Avoid in patients with porphyria because carisoprodol may be porphyrinogenic.
Avoid driving or operating machinery until you know how SOMA affects you, as it may cause drowsiness or dizziness.,Do not consume alcohol or other CNS depressants (e.g., benzodiazepines, opioids) while taking SOMA.,Take exactly as prescribed; do not increase dose or duration due to risk of dependence and withdrawal.,Store securely to prevent misuse; dispose of unused medication properly.,Contact your doctor if you experience severe drowsiness, confusion, or signs of allergic reaction.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants while taking this drug.,Take only as prescribed; do not increase dose or frequency. This drug has abuse potential.,Inform your doctor if you have a history of drug or alcohol abuse, seizures, or liver/kidney disease.,Do not use for longer than 2-3 weeks unless directed by your doctor.
"Somatostatin, a potent inhibitor of growth hormone and insulin secretion, may antagonize the effects of methohexital, a barbiturate anesthetic, by altering glucose metabolism and hemodynamic stability. This interaction can lead to reduced efficacy of methohexital, requiring higher doses for induction of anesthesia, and may increase the risk of prolonged recovery or adverse cardiovascular events. Clinically, patients may experience unpredictable depth of anesthesia or delayed emergence."
"Concurrent administration of somatostatin and pentobarbital may lead to enhanced CNS depression and increased risk of hypotension. Somatostatin inhibits the release of several hormones and can potentiate the sedative effects of pentobarbital through additive central nervous system depression. Clinically, this interaction may result in excessive sedation, respiratory depression, and cardiovascular instability, particularly in elderly or debilitated patients."
"Somatostatin inhibits the release of growth hormone and various gastrointestinal hormones, leading to reduced hepatic blood flow and decreased metabolic clearance of coadministered drugs. Thiopental undergoes extensive hepatic metabolism and its clearance may be impaired by somatostatin-induced reduction in hepatic perfusion, potentially resulting in prolonged anesthesia and increased risk of respiratory depression or hypotension. Additionally, somatostatin may directly enhance the central nervous system depressant effects of thiopental, although the clinical significance of this interaction is variable."
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOMA vs CARISOPRODOL COMPOUND, answered by our medical review team.
SOMA is a Skeletal Muscle Relaxant that works by Centrally acting muscle relaxant; acts at brainstem reticular formation and spinal cord levels to inhibit polysynaptic reflexes, possibly via GABAergic and monoaminergic pathways.. CARISOPRODOL COMPOUND is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOMA and CARISOPRODOL COMPOUND depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOMA is: 250 mg to 350 mg orally three times daily and at bedtime.. The standard adult dose of CARISOPRODOL COMPOUND is: 1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOMA and CARISOPRODOL COMPOUND in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOMA is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal resorptions and skeletal anomalies. Second/third trimester: Risk of neonatal with. CARISOPRODOL COMPOUND is classified as Category A/B. Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.